The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response
Niamh Coleman, Bingnan Zhang, Lauren A. Byers, Timothy A. Yap
Abstract
The therapeutic landscape of drugs targeting the DNA damage response (DDR) is rapidly expanding; however, an urgent unmet need remains for validated predictive biomarkers of response. SLFN11 has emerged as a promising predictor of sensitivity to DNA-damaging chemotherapies, and recently, been associated with sensitivity to PARP inhibition. We discuss its use as a predictive biomarker of response for targeting the DDR.
Topics & Concepts
BiomarkerDNA damagePredictive valueMedicineCancer researchOncologyBioinformaticsComputational biologyBiologyDNAInternal medicineGeneticsPARP inhibition in cancer therapyCancer therapeutics and mechanismsDNA Repair Mechanisms